Skip to main content

AstraZeneca scraps £450m vaccine plant in Liverpool after Labour funding cut

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget, was dependent on a "mutual agreement" with the Treasury and third parties, it was said at the time.

It will no longer go ahead because Labour ministers have offered less funding than their predecessors, the pharmaceutical giant said. An AstraZeneca spokesperson told Sky News: "Following discussions with the current government, we are no longer pursuing our planned investment at Speke. "Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government's proposal."

The money would have expanded an existing site in Speke and was hailed at the time as a "vote of confidence" in Liverpool and the UK's life science sector. The AstraZeneca spokesperson said that the Speke site "will continue to produce and supply our flu vaccine, for patients in the UK and around the world".

A government spokesperson said a "change in the make-up of the investment" proposed by AstraZeneca had "led to a reduced government grant offer being put forward". The spokesperson added: "All government grant funding has to demonstrate value for the taxpayer and unfortunately, despite extensive work from government officials, it has not been possible to achieve a solution.

"AstraZeneca remains closely engaged with the government's work to develop our new industrial strategy, and more broadly we continue to have a thriving life sciences sector, worth £108 billion to the economy and providing over 300,000 highly skilled jobs across the country." The decision is a blow to Rachel Reeves's renewed attempts to deliver economic growth. In a speech earlier this week which named AstraZeneca, the chancellor said life sciences would be key to boosting the economy. She announced plans to deliver an Oxford-Cambridge growth corridor, which she claimed would add up to £78bn to the public coffers.

Jeremy Hunt speaks to the media during a visit to the AstraZeneca Speke Factory.  Pic: HM Treasury

Image: Jeremy Hunt speaks to the media during a visit to the AstraZeneca Speke Factory. Pic: HM Treasury

Andrew Griffith, the shadow business secretary, said: "There's no vaccine for incompetence. In the same week they talked about growth, Labour seem to have fumbled a deal with AstraZeneca, one of the UK's largest companies and central to the critical life sciences sector." The new plant at Speke was intended to enhance the UK's pandemic preparedness. Reports that it was under threat emerged shortly after Labour won the general election, when ministers warned of the need to make cuts to infrastructure projects to fill a £22bn "black hole" in the public finances. The confirmation comes after former health secretary Matt Hancock said that the UK needed to improve its own vaccine manufacturing capability as a "critical" part of preparing for a future pandemic. Mr Hancock told the COVID Inquiry earlier in January that Britain's vaccine manufacturing capacity was "weak".

He added: "Having that manufacture and fill and finish onshore, physically within the UK, is critical in the way that it simply isn't in normal times."

https://worldnewsguru.us/?p=19461&network_id=

Comments

Popular posts from this blog

Dollar set for best week since November on US rates, economic outlook

By Rae Wee SINGAPORE () -The dollar was on track for its best weekly performance in over a month on Friday, underpinned by expectations of fewer Federal Reserve rate cuts this year and the view that the U.S. economy will continue to outperform the rest of its peers globally. The greenback began the new year on a strong note reaching a more than two-year high of 109.54 against a basket of currencies on Thursday as it extended a stellar rally from last year. Its charge higher has come on the back of a more hawkish Fed and a resilient U.S. economy. "Looks like dollar strength is here to stay for now in early 2025 given the U.S. exceptionalism story is here to stay, and it still comes with high U.S. yields," said Charu Chanana, chief investment strategist at Saxo. "Add to that the uncertainty from policies of the incoming (Donald) Trump administration, and you also get the safety aspect of the dollar looking attractive." Ahead of U.S. President-elect Trump'...

Stocks and dollar end 2024 steady, 2025 all about Trump

By Ankur Banerjee and Alun John SINGAPORE/LONDON () -World stocks held steady on Tuesday in cautious year-end trading that has seen investors bracing for the incoming Donald Trump administration by scaling back bets on deep U.S. interest rate cuts in 2025, helping the dollar stand tall against most other currencies. Volumes were light with a holiday for the New Year looming, with the Santa-rally largely failing to materialise as elevated Treasury yields weigh on high equity valuations and boost the greenback. MSCI's world share index was flat on the day, but set to wrap up 2025 with a 16% annual gain. This year's rally has been largely a U.S. phenomenon, with the having risen around 24% compared with an 8% gain for MSCI's broadest index of Asia-Pacific shares outside Japan, and just 5% for Europe's . () But the mood latterly has been more cautious on the back of higher U.S. Treasury yields. The yield on the 10-year note reached 4.64% late last week, its highest...

US Senate planning Jan. 16 hearing for Trump Treasury pick Bessent, Politico reports

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media  would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ...